|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Ariad_Pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:2020
gptkb:Gilead_Sciences
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:ceo
|
gptkb:Dr._Behzad_Aghazadeh
|
|
gptkbp:clinical_trial
|
gptkb:Dr._Sarah_Johnson
gptkb:2020
ongoing
Phase 1
Phase 2
Phase 3
multiple successful trials
|
|
gptkbp:collaborations
|
academic institutions
leading research institutions
|
|
gptkbp:community_involvement
|
various health initiatives
|
|
gptkbp:employees
|
~300
|
|
gptkbp:focus
|
oncology
|
|
gptkbp:founded
|
gptkb:1982
|
|
gptkbp:founder
|
gptkb:Dr._David_M._Goldenberg
|
|
gptkbp:headquarters
|
gptkb:Morris_Plains,_New_Jersey
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Immunomedics, Inc.
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
multiple patents in oncology
|
|
gptkbp:investment
|
various venture capital firms
significant R& D investments
|
|
gptkbp:key_people
|
gptkb:Dr._Behzad_Aghazadeh
gptkb:Dr._David_M._Goldenberg
gptkb:Dr._Robert_A._Gallo
gptkb:Dr._Michael_A._Pehl
|
|
gptkbp:leadership
|
diverse leadership team
|
|
gptkbp:market_cap
|
$21 billion (2020)
|
|
gptkbp:mission
|
improve patient outcomes
|
|
gptkbp:notable_products
|
gptkb:Trodelvy
|
|
gptkbp:partnerships
|
various pharmaceutical companies
|
|
gptkbp:products
|
multiple candidates in development
|
|
gptkbp:research
|
gptkb:Dr._John_M._Kessler
|
|
gptkbp:research_areas
|
gptkb:healthcare_organization
antibody-drug conjugates
urothelial cancer
other solid tumors
|
|
gptkbp:revenue
|
$100 million (2020)
|
|
gptkbp:strategic_importance
|
foster innovation
build partnerships
expand product offerings
increase patient access
enhance market presence
|
|
gptkbp:sustainability_initiatives
|
environmental responsibility
|
|
gptkbp:symbol
|
IMMU
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:values
|
integrity, innovation, collaboration
|
|
gptkbp:vision
|
innovative therapies
|
|
gptkbp:website
|
www.immunomedics.com
|